{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:20:22Z","timestamp":1791404422251,"version":"4.3.3"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0E6517N"],"award-info":[{"award-number":["G0E6517N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.biopha.2023.114305","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:33:07Z","timestamp":1675193587000},"page":"114305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-5299","authenticated-orcid":false,"given":"Bert","family":"Kwanten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Deconick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-1153","authenticated-orcid":false,"given":"Dirk","family":"Daelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114305_bib1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.114305_bib2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2023.114305_bib3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114305_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114305_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114305_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2023.114305_bib7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114305_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/srep42728","article-title":"Identification of a novel NAMPT inhibitor by CRISPR\/Cas9 chemogenomic profiling in mammalian cells","volume":"7","author":"Estoppey","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.114305_bib9","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1038\/s41467-018-06651-x","article-title":"Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers","volume":"9","author":"Ding","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114305_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0665-3","article-title":"Identifying chemogenetic interactions from CRISPR screens with drugZ","volume":"11","author":"Colic","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.biopha.2023.114305_bib11","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1038\/s41467-018-06676-2","article-title":"CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response","volume":"9","author":"Szlachta","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114305_bib12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/1535-7163.MCT-19-1131","article-title":"A genome-scale CRISPR screen identifies the ERBB and mTOR signaling networks as key determinants of response to PI3K inhibition in pancreatic cancer","volume":"19","author":"Milton","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.114305_bib13","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","article-title":"Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2023.114305_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114305_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","article-title":"P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2023.114305_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0092-8674(00)80371-2","article-title":"CRM1 is an export receptor for Leucine-rich nuclear export signals","volume":"90","author":"Fornerod","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.114305_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 \u2014 from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114305_bib18","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.212285299","article-title":"A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export","volume":"99","author":"Daelemans","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.114305_bib19","doi-asserted-by":"crossref","first-page":"9487","DOI":"10.1016\/j.bmc.2008.09.051","article-title":"Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure-activity relationship and mechanism of action","volume":"16","author":"Van Neck","year":"2008","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.biopha.2023.114305_bib20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10822-012-9611-9","article-title":"Consensus induced fit docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors","volume":"26","author":"Kalid","year":"2012","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.biopha.2023.114305_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.chembiol.2014.11.015","article-title":"Identifying drug-target selectivity of small-molecule CRM1\/XPO1 inhibitors by CRISPR\/Cas9 genome editing","volume":"22","author":"Neggers","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.biopha.2023.114305_bib22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41467-017-02349-8","article-title":"Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes","volume":"9","author":"Neggers","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114305_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2023.114305_bib24","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Lapalombella","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.12231","article-title":"KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia","volume":"161","author":"Etchin","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2023.114305_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114305_bib27","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114305_bib28","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.biopha.2023.114305_bib29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ajh.26261","article-title":"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk","volume":"96","author":"Richard","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.114305_bib30","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","article-title":"Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia","volume":"125","author":"Hing","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib31","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","article-title":"XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus","volume":"22","author":"Ranganathan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114305_bib32","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1182\/blood.V128.22.5662.5662","article-title":"The synergistic effect of melphalan and XPO1 inhibition in pre-clinical models of multiple myeloma","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.canlet.2016.09.016","article-title":"Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone","volume":"383","author":"Muqbil","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.114305_bib34","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V128.22.3298.3298","article-title":"Synergistic anti-tumor effect of KPT-8602, a second generation selective inhibitor of nuclear export (SINE) compound, and panobinostat, a pan-histone deacetylase (HDAC) inhibitor in multiple myeloma","volume":"128","author":"Argueta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33784-2","article-title":"Dual inhibition of Bcl-2\/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems","volume":"8","author":"Shang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.114305_bib36","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.clml.2019.07.085","article-title":"Dual inhibition of MDM2 and XPO1 induces synergistic apoptosis in wild-type p53 acute myeloid leukemia through nuclear accumulation of p53 and suppression of c-Myc","volume":"19","author":"Nishida","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.biopha.2023.114305_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/bloodadvances.2019000359","article-title":"Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies","volume":"4","author":"Fischer","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2023.114305_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-134807","article-title":"Inhibiting the nuclear exporter XPO1 and the antiapoptotic factor BCL2 is synergistic in XPO1 mutant and wildtype lymphoma","volume":"136","author":"Owusu-Ansah","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2021.01.008","article-title":"XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a","volume":"503","author":"Wang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.114305_bib40","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1158\/1078-0432.CCR-20-1315","article-title":"The XPO1 inhibitor KPT-8602 synergizes with dexamethasone in acute lymphoblastic Leukemia","volume":"26","author":"Verbeke","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114305_bib41","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.18632\/oncotarget.28047","article-title":"Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status","volume":"12","author":"Marijon","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114305_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.gastro.2021.03.022","article-title":"Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer","volume":"161","author":"Inoue","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2023.114305_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01114-1","article-title":"PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia","volume":"14","author":"Govaerts","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114305_bib44","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3390\/cancers12061574","article-title":"Cotargeting of XPO1 enhances the antileukemic activity of midostaurin and gilteritinib in acute myeloid leukemia","volume":"12","author":"Brinton","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.114305_bib45","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/2159-8290.CD-19-0298","article-title":"Altered nuclear export signal recognition as a driver of oncogenesis","volume":"9","author":"Taylor","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.114305_bib46","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-116500","article-title":"E2F1 is a biomarker of selinexor resistance in relapsed\/refractory multiple myeloma patients","volume":"132","author":"Lagana","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-116663","article-title":"Results of the pivotal STORM study (Part 2) in penta-refractory multiple myeloma (MM): deep and durable responses with oral selinexor plus low dose dexamethasone in patients with penta-refractory MM","volume":"132","author":"Chari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib48","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1535-7163.MCT-19-0977","article-title":"NRG1\/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors","volume":"19","author":"Miyake","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.114305_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150522","article-title":"Transcriptomic correlates of response to selinexor in multiple myeloma reveal a predictive signature","volume":"138","author":"Restrepo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib50","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0006-291X(02)02971-6","article-title":"Molecular cloning and characterization of the human ASB-8 gene encoding a novel member of ankyrin repeat and SOCS box containing protein family","volume":"300","author":"Liu","year":"2003","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2023.114305_bib51","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1074\/jbc.M113.534602","article-title":"Protein interaction screening for the ankyrin repeats and suppressor of cytokine signaling (SOCS) box (ASB) family identify asb11 as a novel endoplasmic reticulum resident ubiquitin ligase","volume":"289","author":"Andresen","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114305_bib52","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1534\/g3.117.041277","article-title":"Evaluation and design of genome-wide CRISPR\/SpCas9 knockout screens","volume":"7","author":"Hart","year":"2017","journal-title":"Genes Genomes Genet."},{"key":"10.1016\/j.biopha.2023.114305_bib53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1101\/gr.245571.118","article-title":"Beta-binomial modeling of CRISPR pooled screen data identifies target genes with greater sensitivity and fewer false negatives","volume":"29","author":"Jeong","year":"2019","journal-title":"Genome Res."},{"key":"10.1016\/j.biopha.2023.114305_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15178","article-title":"Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens","volume":"8","author":"Morgens","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114305_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2023.114305_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2023.114305_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2023.114305_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.biopha.2023.114305_bib59","doi-asserted-by":"crossref","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","article-title":"The reactome pathway knowledgebase","volume":"46","author":"Fabregat","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2023.114305_bib60","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2023.114305_bib61","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.114305_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.biopha.2023.114305_bib63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","article-title":"On the exact distribution of maximally selected rank statistics","volume":"43","author":"Hothorn","year":"2003","journal-title":"Comput. Stat. Data Anal."},{"key":"10.1016\/j.biopha.2023.114305_bib64","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/bimj.200310030","article-title":"Assessment of optimal selected prognostic factors","volume":"46","author":"Lausen","year":"2004","journal-title":"Biometric. J."},{"key":"10.1016\/j.biopha.2023.114305_bib65","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948150","article-title":"STK 38 kinase acts as XPO 1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes","volume":"20","author":"Martin","year":"2019","journal-title":"EMBO Rep."},{"key":"10.1016\/j.biopha.2023.114305_bib66","doi-asserted-by":"crossref","first-page":"68842","DOI":"10.18632\/oncotarget.11995","article-title":"Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export","volume":"7","author":"Neggers","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114305_bib67","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2023.114305_bib68","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41375-020-0708-1","article-title":"Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells","volume":"34","author":"Than","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2023.114305_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkn863","article-title":"Reactome knowledgebase of human biological pathways and processes","volume":"37","author":"Matthews","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2023.114305_bib70","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: the universal protein knowledgebase in 2021","volume":"49","author":"Bateman","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2023.114305_bib71","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-3-319-46503-6_13","article-title":"The Ccr4-not complex: architecture and structural insights","volume":"83","author":"Collart","year":"2017","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.biopha.2023.114305_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1393","article-title":"AUF1 regulation of coding and noncoding RNA","volume":"8","author":"White","year":"2017","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.biopha.2023.114305_bib73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2478\/s11658-008-0002-0","article-title":"hnRNP-R regulates the PMA-induced c-fos expression in retinal cells","volume":"13","author":"Huang","year":"2008","journal-title":"Cell Mol. Biol. Lett."},{"key":"10.1016\/j.biopha.2023.114305_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fmolb.2018.00079","article-title":"Systematic analysis of gene expression profiles controlled by hnRNP Q and hnRNP R, two closely related human RNA binding proteins implicated in mRNA processing mechanisms","volume":"5","author":"Cappelli","year":"2018","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biopha.2023.114305_bib75","doi-asserted-by":"crossref","first-page":"38098","DOI":"10.1074\/jbc.M605271200","article-title":"Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export","volume":"281","author":"Jiao","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114305_bib76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cytogfr.2014.04.009","article-title":"The role of bone morphogenetic proteins in myeloma cell survival","volume":"25","author":"Holien","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2023.114305_bib77","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1083\/jcb.200612129","article-title":"Notch signaling is necessary for epithelial growth arrest by TGF-\u03b2","volume":"176","author":"Niimi","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114305_bib78","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.200305112","article-title":"Cross-talk between the Notch and TGF-\u03b2 signaling pathways mediated by interaction of the Notch intracellular domain with Smad3","volume":"163","author":"Blokzijl","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114305_bib79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2853","article-title":"TGFbeta signalling: a complex web in cancer progression","volume":"10","author":"Ikushima","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.114305_bib80","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1038\/s41467-020-18784-z","article-title":"Contribution of GATA6 to homeostasis of the human upper pilosebaceous unit and acne pathogenesis","volume":"11","author":"Oul\u00e8s","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114305_bib81","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1073\/pnas.97.3.1014","article-title":"A nuclear export signal in the N-terminal regulatory domain of I\u03baB\u03b1 controls cytoplasmic localization of inactive NF-\u03baB\/I\u03baB\u03b1 complexes","volume":"97","author":"Huang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.114305_bib82","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1074\/jbc.274.13.9108","article-title":"Nuclear retention of I\u03baB\u03b1 protects it from signal-induced degradation and inhibits nuclear factor \u03baB transcriptional activation","volume":"274","author":"Rodriguez","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114305_bib83","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1093\/emboj\/18.23.6682","article-title":"An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of Ikappa Balpha","volume":"18","author":"Johnson","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2023.114305_bib84","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5660.5660","article-title":"Efficacy of selinexor is dependent on I\u03baB-\u03b1 expression and NF-Kb deactivation in multiple myeloma cells","volume":"128","author":"Kashyap","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.114305_bib85","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB-\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114305_bib86","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114305_bib87","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2018.01.078","article-title":"TFCP2\/TFCP2L1\/UBP1 transcription factors in cancer","volume":"420","author":"Kotarba","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.114305_bib88","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.114305_bib89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jbior.2017.06.003","article-title":"GSK3 and its interactions with the PI3K\/AKT\/mTOR signalling network","volume":"65","author":"Hermida","year":"2017","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.biopha.2023.114305_bib90","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.immuni.2008.01.009","article-title":"TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor","volume":"28","author":"Gardam","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2023.114305_bib91","doi-asserted-by":"crossref","first-page":"32277","DOI":"10.1074\/jbc.M111.236448","article-title":"A20-binding inhibitor of nuclear factor-\u03baB (NF-\u03baB)-2 (ABIN-2) is an activator of inhibitor of NF-\u03baB (I\u03baB) kinase \u03b1 (IKK\u03b1)-mediated NF-\u03baB transcriptional activity","volume":"286","author":"Leotoing","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114305_bib93","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.virol.2019.04.004","article-title":"E3 ligase ASB8 promotes porcine reproductive and respiratory syndrome virus proliferation by stabilizing the viral Nsp1\u03b1 protein and degrading host IKK\u03b2 kinase","volume":"532","author":"Li","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.biopha.2023.114305_bib94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molimm.2020.03.011","article-title":"E3 ubiquitin ligase ASB8 negatively regulates interferon via regulating TBK1\/IKKi homeostasis","volume":"121","author":"Guo","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.biopha.2023.114305_bib95","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrc3310","article-title":"Kinesins and cancer","volume":"12","author":"Rath","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.114305_bib96","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btu016","article-title":"Prediction of nuclear export signals using weighted regular expressions (Wregex)","volume":"30","author":"Prieto","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2023.114305_bib97","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/bioinformatics\/btu826","article-title":"LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins","volume":"31","author":"Xu","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2023.114305_bib98","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-16-1580","article-title":"The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia","volume":"23","author":"Vercruysse","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114305_bib99","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/embo-reports\/kvd029","article-title":"Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal","volume":"1","author":"Watanabe","year":"2000","journal-title":"EMBO Rep."},{"key":"10.1016\/j.biopha.2023.114305_bib100","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11466","article-title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning","volume":"4","author":"K\u0131rl\u0131","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.biopha.2023.114305_bib101","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/scdb.1996.0122","article-title":"HnRNP proteins and the nuclear export of mRNA","volume":"8","author":"Pi\u00f1ol-Roma","year":"1997","journal-title":"Semin Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2023.114305_bib102","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/1098-2744(200006)28:2<76::AID-MC3>3.0.CO;2-0","article-title":"Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue","volume":"28","author":"Blaxall","year":"2000","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.biopha.2023.114305_bib103","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbcan.2005.10.002","article-title":"The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression","volume":"1765","author":"Carpenter","year":"2006","journal-title":"Biochim. Biophys. Acta (BBA) - Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.114305_bib104","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/10428194.2010.546914","article-title":"BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention","volume":"52","author":"Perrotti","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2023.114305_bib105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ng.2508","article-title":"Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia","volume":"45","author":"De Keersmaecker","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2023.114305_bib106","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-018-0650-0","article-title":"The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models","volume":"11","author":"Vicente","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114305_bib107","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1091\/mbc.e12-01-0045","article-title":"NESdb: a database of NES-containing CRM1 cargoes","volume":"23","author":"Xu","year":"2012","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.biopha.2023.114305_bib108","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","article-title":"High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities","volume":"163","author":"Hart","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.114305_bib109","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.1246981","article-title":"Genetic screens in human cells using the CRISPR-Cas9 system","volume":"343","author":"Wang","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.114305_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009387","article-title":"Intermedilysin cytolytic activity depends on heparan sulfates and membrane composition","volume":"17","author":"Drabavicius","year":"2021","journal-title":"PLOS Genet."},{"key":"10.1016\/j.biopha.2023.114305_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109597","article-title":"Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome","volume":"36","author":"Parrish","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2023.114305_bib112","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41467-021-21478-9","article-title":"Combinatorial CRISPR screen identifies fitness effects of gene paralogues","volume":"12","author":"Thompson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114305_bib113","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.18632\/oncotarget.6495","article-title":"A method for quantification of exportin-1 (XPO1) occupancy by selective inhibitor of nuclear export (SINE) compounds","volume":"7","author":"Crochiere","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114305_bib114","series-title":"Nuclear export receptor CRM1 recognizes nuclear export signals with diverse conformations (Doctoral dissertation)","author":"Fung","year":"2017"},{"key":"10.1016\/j.biopha.2023.114305_bib115","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1242\/jcs.057026","article-title":"Repression of classical nuclear export by S-nitrosylation of CRM1","volume":"122","author":"Wang","year":"2009","journal-title":"J. Cell Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:44:59Z","timestamp":1776771899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":114,"alternative-id":["S0753332223000938"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114305","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114305"}}